Progress and prospects for engineered T cell therapies

Area of Science:

• Immunotherapy
• Cellular Therapy
• Gene Therapy

Background:

• Engineered T cells represent a promising frontier in cellular therapy.
• Recombinant T cell receptors (TCRs) and chimeric antigen receptors (CARs) are being investigated for targeting tumor and viral antigens.
• Gene transfer methods, including viral and nonviral approaches, are employed for T cell modification.

Purpose of the Study:

• To review the progress in engineered T cell therapies.
• To discuss advancements in antigen receptor therapies.
• To consider the role of emerging gene-editing technologies in this field.

Main Methods:

• Review of existing proof-of-concept studies and recent clinical investigations.
• Analysis of viral and nonviral gene transfer techniques for T cells.
• Examination of autologous and allogeneic T cell transfer strategies.

Main Results:

• Notable successes have been achieved with viral vector-mediated transfer of CARs targeting B cell antigens.
• Studies report both anticipated and unanticipated complications associated with these therapies.
• Ongoing research explores diverse approaches for engineered T cell development.

Conclusions:

• Engineered T cell therapy holds significant therapeutic potential.
• Continued research is essential to overcome challenges and optimize treatment efficacy.
• Gene-editing technologies offer new avenues for advancing antigen receptor therapies.